Cell Genesys added to the growing list of therapeutic prostate cancer vaccine failures today with the announcement that the second phase III trial of its GVAX immunotherapy has been halted.
The decision was made after a futility analysis concluded the trial, called Vital-1, had less than a 30% chance of establishing an improvement in survival. With both pivotal trials now terminated, the company and its partner Takeda will review the programme, but the prognosis is poor. Cell Genesys is culling three-quarters of its staff and considering its options, including selling up and liquidating; shares in the company plunged 73% to a new low of 16 cents on the news.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.